Skip to main content

Welkom bij THIM Hogeschool voor Fysiotherapie & Bohn Stafleu van Loghum

THIM Hogeschool voor Fysiotherapie heeft ervoor gezorgd dat je Mijn BSL eenvoudig en snel kunt raadplegen. Je kunt je links eenvoudig registreren. Met deze gegevens kun je thuis, of waar ook ter wereld toegang krijgen tot Mijn BSL. Heb je een vraag, neem dan contact op met helpdesk@thim.nl.

Registreer

Om ook buiten de locaties van THIM, thuis bijvoorbeeld, van Mijn BSL gebruik te kunnen maken, moet je jezelf eenmalig registreren. Dit kan alleen vanaf een computer op een van de locaties van THIM.

Eenmaal geregistreerd kun je thuis of waar ook ter wereld onbeperkt toegang krijgen tot Mijn BSL.

Login

Als u al geregistreerd bent, hoeft u alleen maar in te loggen om onbeperkt toegang te krijgen tot Mijn BSL.

Top
Gepubliceerd in:

01-08-2001 | Beschouwing

Hormonen na de overgang: goed voor hart- en bloedvaten?

Auteur: Dr. MJJ de Kleijn

Gepubliceerd in: Huisarts en wetenschap | Uitgave 8/2001

Log in om toegang te krijgen
share
DELEN

Deel dit onderdeel of sectie (kopieer de link)

  • Optie A:
    Klik op de rechtermuisknop op de link en selecteer de optie “linkadres kopiëren”
  • Optie B:
    Deel de link per e-mail

semenvatting

Postmenopauzale vrouwen hebben een verhoogd risico op hart- en vaatziekten vergeleken met premenopauzale vrouwen. Dit artikel vat de resultaten samen van het wetenschappelijk onderzoek naar de effecten van hormoontherapie (oestrogenen en progestagenen) op hart- en vaatziekten bij postmenopauzale vrouwen.
Hormoontherapie beïnvloedt het lipidenprofiel, de vasodilatie van slagaders en de mate van atherosclerose gunstig. Tijdens het gebruik van hormoontherapie neemt de stollingsactiviteit echter toe. In observationeel onderzoek wordt een sterke afname van het risico op hart- en vaatziekten in hormoongebruiksters gevonden. Deze bevindingen worden echter niet bevestigd door de resultaten van de eerste ‘randomized controlled trials’. Het risico op veneuze trombose en borstkanker neemt toe door hormoongebruik. Het zoeken naar alternatieven zoals selectieve oestrogeen receptor modulatoren (SERM&'s) en plantaardige (phyto) oestrogenen is nog in volle gang.
Op dit moment is er in de huisartsenpraktijk geen plaats voor de behandeling van postmenopauzale vrouwen met hormoontherapie ter voorkoming van hart- en vaatziekten.
Literatuur
go back to reference Elders P, Van Keimpema JC, Petri H, et al. NHG-Standaard Osteoporose. Huisarts Wet 1999;42:115-128. Elders P, Van Keimpema JC, Petri H, et al. NHG-Standaard Osteoporose. Huisarts Wet 1999;42:115-128.
go back to reference Stampfer MJ, Colditz GA. Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence. Prev Med 1991;20:47-63.CrossRef Stampfer MJ, Colditz GA. Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence. Prev Med 1991;20:47-63.CrossRef
go back to reference Grady D, Rubin SM, Petitti DB, et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 1992;117:1016-1037.CrossRef Grady D, Rubin SM, Petitti DB, et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 1992;117:1016-1037.CrossRef
go back to reference Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 1998; 280:605-613.CrossRef Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 1998; 280:605-613.CrossRef
go back to reference The Writing Group for the PEPI Trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. JAMA 1995;273:199-208.CrossRef The Writing Group for the PEPI Trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. JAMA 1995;273:199-208.CrossRef
go back to reference Herrington DM, Werbel BL, Riley WA, et al. Individual and combined effects of estrogen/ progestin therapy and lovastatin on lipids and flow-mediated vasodilation in postmenopausal women with coronary artery disease. J Am Coll Cardiol 1999;33:2030-2037.CrossRef Herrington DM, Werbel BL, Riley WA, et al. Individual and combined effects of estrogen/ progestin therapy and lovastatin on lipids and flow-mediated vasodilation in postmenopausal women with coronary artery disease. J Am Coll Cardiol 1999;33:2030-2037.CrossRef
go back to reference Darling GM, Johns JA, McCloud PI, Davis SR. Estrogen and progestin compared with simvastatin for hypercholesterolemia in postmenopausal women. N Engl J Med 1997;337:595-601.CrossRef Darling GM, Johns JA, McCloud PI, Davis SR. Estrogen and progestin compared with simvastatin for hypercholesterolemia in postmenopausal women. N Engl J Med 1997;337:595-601.CrossRef
go back to reference Espeland MA, Marcovina SM, Miller V, et al. Effect of postmenopausal hormone therapy on lipoprotein(a) concentration. Circulation 1998; 97:979-986.CrossRef Espeland MA, Marcovina SM, Miller V, et al. Effect of postmenopausal hormone therapy on lipoprotein(a) concentration. Circulation 1998; 97:979-986.CrossRef
go back to reference Walsh BW, Schiff I, Rosner B, et al. Effects of postmenopausal estrogen replacement on the concentrations and metabolism of plasma lipoproteins. N Engl J Med 1991;325:1196-1204.CrossRef Walsh BW, Schiff I, Rosner B, et al. Effects of postmenopausal estrogen replacement on the concentrations and metabolism of plasma lipoproteins. N Engl J Med 1991;325:1196-1204.CrossRef
go back to reference Herrington DM, Braden GA, Williams JK, Morgan TM. Endothelial-dependent coronary vasomotor responsiveness in postmenopausal women with and without estrogen replacement therapy. Am J Cardiol 1994;73:951-952.CrossRef Herrington DM, Braden GA, Williams JK, Morgan TM. Endothelial-dependent coronary vasomotor responsiveness in postmenopausal women with and without estrogen replacement therapy. Am J Cardiol 1994;73:951-952.CrossRef
go back to reference Gerhard M, Walsh BW, Tawakol A, et al. Estradiol therapy combined with progesterone and endothelium-dependent vasodilation in postmenopausal women. Circulation 1998; 98:1158-1163.CrossRef Gerhard M, Walsh BW, Tawakol A, et al. Estradiol therapy combined with progesterone and endothelium-dependent vasodilation in postmenopausal women. Circulation 1998; 98:1158-1163.CrossRef
go back to reference De Kleijn MJJ. Hormone replacement therapy and endothelial function. Epidemiologic studies on estrogen and cardiovascular disease in post-menopausal women. 2000; 100–111. Thesis. Julius Center for General Practice and Patient Oriented Research, University Medical Center Utrecht. De Kleijn MJJ. Hormone replacement therapy and endothelial function. Epidemiologic studies on estrogen and cardiovascular disease in post-menopausal women. 2000; 100–111. Thesis. Julius Center for General Practice and Patient Oriented Research, University Medical Center Utrecht.
go back to reference Van Baal WM, Kenemans P, Emeis JJ, et al. Long-term effects of combined hormone replacement therapy on markers of endothelial function and inflammatory activity in healthy postmenopausal women. Fertil Steril 1999; 71:663-670.CrossRef Van Baal WM, Kenemans P, Emeis JJ, et al. Long-term effects of combined hormone replacement therapy on markers of endothelial function and inflammatory activity in healthy postmenopausal women. Fertil Steril 1999; 71:663-670.CrossRef
go back to reference McCrohon JA, Adams MR, McCredie RJ, et al. Hormone replacement therapy is associated with improved arterial physiology in healthy post-menopausal women. Clinical Endocrinology 1996;45:435-441.CrossRef McCrohon JA, Adams MR, McCredie RJ, et al. Hormone replacement therapy is associated with improved arterial physiology in healthy post-menopausal women. Clinical Endocrinology 1996;45:435-441.CrossRef
go back to reference Sorensen KE, Dorup I, Hermann AP, Mosekilde L. Combined hormone replacement therapy does not protect women against the agerelated decline in endothelium-dependent vasomotor function. Circulation 1998;97: 234–1238.CrossRef Sorensen KE, Dorup I, Hermann AP, Mosekilde L. Combined hormone replacement therapy does not protect women against the agerelated decline in endothelium-dependent vasomotor function. Circulation 1998;97: 234–1238.CrossRef
go back to reference Westendorp ICD, De Kleijn MJJ, Bots ML, et al. The effect of hormone replacement therapy on arterial distensibility and compliance in peri-menopausal women: a two year randomised trial. Atherosclerosis 2000;152:149-157.CrossRef Westendorp ICD, De Kleijn MJJ, Bots ML, et al. The effect of hormone replacement therapy on arterial distensibility and compliance in peri-menopausal women: a two year randomised trial. Atherosclerosis 2000;152:149-157.CrossRef
go back to reference Espeland MA, Applegate W, Furberg CD, et al. Estrogen replacement therapy and progression of intimal-medial thickness in the carotid arteries of postmenopausal women. ACAPS Investigators. Asymptomatic Carotid Atherosclerosis Progression Study. Am J Epidemiol. 1995;142:1011-1019.CrossRef Espeland MA, Applegate W, Furberg CD, et al. Estrogen replacement therapy and progression of intimal-medial thickness in the carotid arteries of postmenopausal women. ACAPS Investigators. Asymptomatic Carotid Atherosclerosis Progression Study. Am J Epidemiol. 1995;142:1011-1019.CrossRef
go back to reference Herrington DM, Reboussin DM, Brosnihan KB, et al. Effects of estrogen replacement on the progression of coronary-artery atherosclerosis. N Engl J Med 2000;343:522-529.CrossRef Herrington DM, Reboussin DM, Brosnihan KB, et al. Effects of estrogen replacement on the progression of coronary-artery atherosclerosis. N Engl J Med 2000;343:522-529.CrossRef
go back to reference Van Baal WM, Emeis JJ, van der Mooren MJ, et al. Impaired procoagulant-anticoagulant balance during hormone replacement therapy? A randomised, placebo-controlled 12-week study. Thromb Res 2000;83:29-34. Van Baal WM, Emeis JJ, van der Mooren MJ, et al. Impaired procoagulant-anticoagulant balance during hormone replacement therapy? A randomised, placebo-controlled 12-week study. Thromb Res 2000;83:29-34.
go back to reference The Writing Group for the Estradiol Clotting Factors study. Effects on haemostasis of hormone replacement therapy with transdermal estradiol and oral sequential medroxyprogesterone acetate: a one-year, double-blind, placebo-controlled study. Thromb Haemost 1996;75: 476–480.CrossRef The Writing Group for the Estradiol Clotting Factors study. Effects on haemostasis of hormone replacement therapy with transdermal estradiol and oral sequential medroxyprogesterone acetate: a one-year, double-blind, placebo-controlled study. Thromb Haemost 1996;75: 476–480.CrossRef
go back to reference Nabulsi AA, Folsom AR, White A, et al. Association of hormone-replacement therapy with various cardiovascular risk factors in post-menopausal women. The Atherosclerosis Risk in Communities Study Investigators. N Engl J Med 1993;328:1069-1075.CrossRef Nabulsi AA, Folsom AR, White A, et al. Association of hormone-replacement therapy with various cardiovascular risk factors in post-menopausal women. The Atherosclerosis Risk in Communities Study Investigators. N Engl J Med 1993;328:1069-1075.CrossRef
go back to reference Grodstein F, Stampfer MJ, Manson JE, et al. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. N Engl J Med 1996;335:453-461.CrossRef Grodstein F, Stampfer MJ, Manson JE, et al. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. N Engl J Med 1996;335:453-461.CrossRef
go back to reference Women’s Health Initiative Study Group. Design of the Women’s Health Initiative clinical trial and observational study. Control Clin Trials 1998;19:61-109.CrossRef Women’s Health Initiative Study Group. Design of the Women’s Health Initiative clinical trial and observational study. Control Clin Trials 1998;19:61-109.CrossRef
go back to reference Vickers MR, Meade TW, Wilkes HC. Hormone replacement therapy and cardiovascular disease: the case for a randomized controlled trial. Ciba Found Symp 1995;191:150-164.PubMed Vickers MR, Meade TW, Wilkes HC. Hormone replacement therapy and cardiovascular disease: the case for a randomized controlled trial. Ciba Found Symp 1995;191:150-164.PubMed
go back to reference Hemminki E, McPherson K. Impact of post-menopausal hormone therapy on cardiovascular events and cancer: pooled data from clinical trials. BMJ 1997;315:149-153.CrossRef Hemminki E, McPherson K. Impact of post-menopausal hormone therapy on cardiovascular events and cancer: pooled data from clinical trials. BMJ 1997;315:149-153.CrossRef
go back to reference Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy:collaborative reanalysis of data from 51 epidemiological studies of 52 705 women with breast cancer and 108 411 women without breast cancer. Lancet 1997;350:1047-1059.CrossRef Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy:collaborative reanalysis of data from 51 epidemiological studies of 52 705 women with breast cancer and 108 411 women without breast cancer. Lancet 1997;350:1047-1059.CrossRef
go back to reference Colditz GA, Hankinson SE, Hunter DJ, et al. The use of estrogens and progestins and the risk of breast-cancer in post-menopausal women. N Engl J Med 1995;332:1589-1593.CrossRef Colditz GA, Hankinson SE, Hunter DJ, et al. The use of estrogens and progestins and the risk of breast-cancer in post-menopausal women. N Engl J Med 1995;332:1589-1593.CrossRef
go back to reference Gapstur SM, Morrow M, Sellers TA. Hormone replacement therapy and risk of breast cancer with a favorable histology. Results of the Iowa Women’s Health Study. JAMA 1999;281:2091-2097.CrossRef Gapstur SM, Morrow M, Sellers TA. Hormone replacement therapy and risk of breast cancer with a favorable histology. Results of the Iowa Women’s Health Study. JAMA 1999;281:2091-2097.CrossRef
go back to reference Love RR, Newcomb PA, Wiebe DA, et al. Effects of tamoxifen therapy on lipid and lipoprotein levels in postmenopausal patients with node-negative breast cancer. J Natl Cancer Inst 1990;82:1327-1332.CrossRef Love RR, Newcomb PA, Wiebe DA, et al. Effects of tamoxifen therapy on lipid and lipoprotein levels in postmenopausal patients with node-negative breast cancer. J Natl Cancer Inst 1990;82:1327-1332.CrossRef
go back to reference Mijatovic V, Netelenbos C, Van der Mooren MJ, et al. Randomized, double-blind, placebo-controlled study of the effects of raloxifene and conjugated equine estrogen on plasma homo-cystein levels in healthy postmenopausal women. Fertil Steril 1998;70:1085-1089.CrossRef Mijatovic V, Netelenbos C, Van der Mooren MJ, et al. Randomized, double-blind, placebo-controlled study of the effects of raloxifene and conjugated equine estrogen on plasma homo-cystein levels in healthy postmenopausal women. Fertil Steril 1998;70:1085-1089.CrossRef
go back to reference Anderson JW, Johnstone BM, Cook-Newell ME. Meta-analysis of the effects of soy protein intake on serum lipids. N.Engl.J.Med 1995; 333:276-282.CrossRef Anderson JW, Johnstone BM, Cook-Newell ME. Meta-analysis of the effects of soy protein intake on serum lipids. N.Engl.J.Med 1995; 333:276-282.CrossRef
go back to reference Nestel PJ, Yamashita T, Sasahara T, et al. Soy isoflavones improve systemic arterial compliance but not plasma lipids in menopausal and perimenopausal women. Arterioscler Thromb Vasc Biol.1997;17:3392-3398.CrossRef Nestel PJ, Yamashita T, Sasahara T, et al. Soy isoflavones improve systemic arterial compliance but not plasma lipids in menopausal and perimenopausal women. Arterioscler Thromb Vasc Biol.1997;17:3392-3398.CrossRef
go back to reference Vanharanta M, Voutilainen S, Lakka TA, et al. Risk of acute coronary events according to serum concentrations of enterolactone: a prospective population-based case-control study. Lancet 1999;354:2112-2115.CrossRef Vanharanta M, Voutilainen S, Lakka TA, et al. Risk of acute coronary events according to serum concentrations of enterolactone: a prospective population-based case-control study. Lancet 1999;354:2112-2115.CrossRef
Metagegevens
Titel
Hormonen na de overgang: goed voor hart- en bloedvaten?
Auteur
Dr. MJJ de Kleijn
Publicatiedatum
01-08-2001
Uitgeverij
Bohn Stafleu van Loghum
Gepubliceerd in
Huisarts en wetenschap / Uitgave 8/2001
Print ISSN: 0018-7070
Elektronisch ISSN: 1876-5912
DOI
https://doi.org/10.1007/BF03082494